source
- Novartis drops $125M for Sironax’s tech to cross blood-brain barrierNovartis stands alongside Big Pharma peers that have similarly invested in technologies to penetrate the blood-brain barrier, including GSK, Roche and Eli Lilly.BioSpace · 1mo ago↗ source
- Psychedelic therapeutics near first FDA approval as Compass Pathways and Definium report promising resultsBioSpace notes that the psychedelic drug sector is regaining momentum after a setback in 2024 when Lykos’ MDMA therapy failed to win FDA clearance. The focus has shifted to new candidates, with Com…